Table 2.
LS mean (SE) change from baseline in cardiovascular risk markers at 36 months
| Exenatide (n = 511) | Glimepiride (n = 508) | P value for treatment difference | |
|---|---|---|---|
| Body weight (kg) | |||
| n | 185 | 201 | |
| LS mean (SE) | −3.9 (0.33) | 1.3 (0.32) | |
| 95 % CI | −4.6, −3.3 | 0.7, 1.9 | |
| Treatment difference | −5.2 (0.46) | <0.0001 | |
| Waist circumference (cm) | |||
| n | 181 | 199 | |
| LS mean (SE) | −3.6 (0.38) | 0.9 (0.36) | |
| 95 % CI | −4.4, −2.9 | 0.2, 1.6 | |
| Treatment difference | −4.5 (0.28) | <0.001 | |
| Systolic blood pressure (mmHg) | |||
| n | 183 | 203 | |
| LS mean (SE) | −2.5 (0.89) | 2.8 (0.85) | |
| 95 % CI | −4.2, −0.7 | 1.1, 4.4 | |
| Treatment difference | −5.2 (1.23) | <0.001 | |
| Diastolic blood pressure (mmHg) | |||
| n | 183 | 203 | |
| LS mean (SE) | −2.6 (0.55) | −0.9 (0.52) | |
| 95 % CI | −3.7, –1.5 | −1.9, 0.2 | |
| Treatment difference | −1.7 (0.75) | 0.023 | |
| Heart rate (beats per minute) | |||
| n | 181 | 199 | |
| LS mean (SE) | −0.3 (0.58) | 0.4 (0.56) | |
| 95 % CI | −1.4, 0.9 | −0.7, 1.5 | |
| Treatment difference | −0.7 (0.81) | 0.374 | |
| Total cholesterol (mmol/L) | |||
| n | 178 | 193 | |
| LS mean (SE) | 0.1 (0.06) | 0.1 (0.05) | |
| 95 % CI | 0.0, 0.3 | 0.0, 0.2 | |
| Treatment difference | 0.0 (0.08) | 0.791 | |
| LDL-cholesterol (mmol/L) | |||
| n | 171 | 184 | |
| LS mean (SE) | 0.2 (0.05) | 0.1 (0.05) | |
| 95 % CI | 0.1, 0.3 | 0.0, 0.2 | |
| Treatment difference | 0.1 (0.07) | 0.304 | |
| HDL-cholesterol (mmol/L) | |||
| n | 178 | 195 | |
| LS mean (SE) | 0.05 (0.01) | −0.02 (0.01) | |
| 95 % CI | 0.02, 0.07 | −0.04, 0.01 | |
| Treatment difference | 0.06 (0.02) | 0.001 | |
| Triglycerides (mmol/L) | |||
| n | 178 | 193 | |
| LS mean (SE) | −0.2 (0.06) | 0.1 (0.06) | |
| 95 % CI | −0.3, −0.1 | −0.1, 0.2 | |
| Treatment difference | −0.3 (0.09) | 0.004 | |
CI confidence interval, HDL high-density lipoprotein, LDL low-density lipoprotein, LS least-squares, SE standard error